Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology as well as a burgeoning field of genetic medicine, RNA ...

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is ...

Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...

Wave Life Sciences specializes in oligonucleotide therapeutics, leveraging its RNA editing platform to develop treatments for a variety of genetic disorders. The company’s approach aims to provide ...

CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling ...

Wave Life Sciences Ltd . (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, has been making significant ...

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating ...

CRISPR/Cas9 genome editing has captured the attention of the popular media, the scientific community and the investment world: The promise of going into a cell and precisely making changes in its ...